Side-by-side · Research reference
ChonlutenvsGHRP-6
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/38 cited
BPhase 1HUMAN-REVIEWED10/36 cited
Chonluten
Khavinson Bioregulator · Bronchial Mucosa
Oral · Sublingual · Per Protocol
GHRP-6
Hexapeptide GHRP · Strong appetite stimulant
SQ · Multiple sites · 1–3×/day
01Mechanism of Action
Parameter
Chonluten
GHRP-6
Primary target
Bronchial epithelial cells and respiratory mucosa tissue complexes
Ghrelin receptor (GHS-R1a)Bowers 1990
Pathway
Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022
GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002
Downstream effect
Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022
GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002
Feedback intact?
—
—
Origin
Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology
Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990
Antibody development
—
—
02Dosage Protocols
Parameter
Chonluten
GHRP-6
Typical protocol dose
10–20 mg / day
Russian bioregulator tradition dosing; not standardized in Western literature.
—
Frequency
Once or twice daily
1–3× per day
Route
Oral (capsule) or sublingual
Sublingual claimed for enhanced bioavailability; not validated.
—
Duration
10–30 days per cycle
Traditional Khavinson protocol; cyclic administration common.
8–12 weeks on / 4 off
Clinical validation
None (PubMed indexed)
—
Lower / starter dose
—
50 mcg per dose
Reconstitution
—
Bacteriostatic water
Timing
—
Pre-meal preferred for appetite support
04Side Effects & Safety
Parameter
Chonluten
GHRP-6
Documented adverse events
No published safety data in PubMed-indexed literature
—
Theoretical risks
Peptide hypersensitivity, GI intolerance (uncharacterized)
—
Drug interactions
Unknown — no pharmacokinetic studies available
—
Pregnancy / lactation
No data — avoid
—
Hunger
—
Pronounced — defining feature vs ipamorelin
Cortisol elevation
—
Mild
Prolactin elevation
—
Mild
Injection site reaction
—
Mild
Cancer risk
—
Contraindicated in active malignancy
Pregnancy / OB
—
Avoid
Absolute Contraindications
Chonluten
- ·Known hypersensitivity to peptide components
GHRP-6
- ·Active malignancy
- ·Pregnancy / breastfeeding
Relative Contraindications
Chonluten
- ·Pregnancy and lactation (insufficient data)
- ·Active malignancy (theoretical bioregulator concern)
GHRP-6
- ·Severe insulin resistance (appetite-driven caloric load)
05Administration Protocol
Parameter
Chonluten
GHRP-6
1. Preparation
Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
2. Oral route
Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.
SQ — abdomen. Rotate sites.
3. Sublingual route
Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.
Pre-meal for appetite support; pre-sleep for GH alignment.
4. Timing
Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
5. Cycle protocol
10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.
29–31G, 4–8 mm insulin syringe.